ImmunityBio shares rose to their highest level since May 2024 after Chairman Patrick Soon-Shiong teased a three-year expansion plan for Anktiva. He highlighted IL-15 potential to cure cancer on X. This follows the company's recent partnership to launch Anktiva in Saudi Arabia for bladder and lung cancer treatments.